Active ingredientAvapritinibCat. No. P-A219-001CAS 1703793-34-3Family · Pharmaceutical analytical standards
Avapritinib
A KIT and PDGFRA kinase inhibitor, approved in the United States in January 2020 and in Europe the same year for gastrointestinal stromal tumours (GIST) with PDGFRA exon 18 mutations, and later also for systemic mastocytosis. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It was the first targeted therapy approved by the FDA for the rare PDGFRA D842V mutation, a genetic defect that makes these tumours unresponsive to the drugs used before.
Go to the active ingredient →Active ingredientAvapritinibCat. No. P-A219-001CAS 1703793-34-3
Isotopically labelledAvapritinib-13C-d3Cat. No. P-A219-002
ImpurityAvapritinib Impurity 1Cat. No. P-A219-003
ImpurityAvapritinib Impurity 2Cat. No. P-A219-004
ImpurityAvapritinib Impurity 3Cat. No. P-A219-005No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.